自拍无码精品一区二区|亚洲А∨天堂久久精品|国产日韩欧美一区二区视|亚洲av高清dvd丝袜|中文一级无码黄片精品视频|亚洲无码网站在线免费观看|免费无码又爽又刺激又污又黄|成人免费无码婬片在线观看免费

159-2642-3062 027-65317797
服務(wù)熱線(工作日:9:00-17:30)

瀏覽量: 159

  • 產(chǎn)品名稱: Research Grade Ravulizumab ( 雷夫利珠單抗 )
  • 產(chǎn)品貨號: CSD00472
  • 貨期: 現(xiàn)貨
  • 價格與訂購: 2480
  • 數(shù)量:
    庫存: 100
  • 規(guī)格: 100μg
  • 產(chǎn)品信息
  • 如何訂購
    貨號(Catalog No.)
    CSD00472
    通用名INN
    Ravulizumab
    純度(Purity)
    >95%
    濃度( Concentration)
    1mg/ml
    Formulation
    PBS buffer PH7.5
    Source
    CHO cells
    內(nèi)毒素(Endotoxin level)
    Please contact with the lab for this information.
    產(chǎn)品描述(Description)
    Ravulizumab is considered a long-acting complement 5 (C5) inhibitor that has been undergoing clinical trials for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as of 4 February, 2016. A drug similar to ravulizumab (ALXN1210), called eculizumab, is currently approved for the treatment of PNH in 46 countries under the brand name Soliris?. Ravulizumab is considered by Alexion Pharmaceuticals Inc. to be a "next-generation" eculizumab molecule. Ravulizumab was subsequently approved by the US FDA in December of 2018 for a variety of beneficial characteristics that make it an advanced, next-generation agent in comparison to eculizumab. In particular, ravulizumab is currently the first and only long-acting C5 complement inhibitor that can be administered every eight weeks for the treatment of adult patients with PNH whereas eculizumab is a bi-weekly treatment,Label. Moreover, virtually all of the phase 3 trial results for ravulizumab have demonstrated the equivalent efficacy and safety established by eculizumab and that patients transition safely and effectively from using eculizumab to ravulizumab. Subsequently, whereas PNH patients may have needed to previously plan their lives rather strictly around the bi-weekly infusion administrations of eculizumab, with ravulizumab such patients can find a more relaxed dosing schedule of only six or seven infusions over an entire year,Label.
    別名(Alternative names)
    ALXN-1210,ravulizumab-cwvz
    靶點;物種(Specificity target name;species)
    C5[Homo sapiens]
    種類(Species)
    Humanized
    受體鑒定(Receptor identification)
    IgG2-G4-kappa
    CAS
    1803171-55-2
    存儲條件(Storage)
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Store at +4°C short term (1-2 weeks).
    Store at -20 °C 12 months.
    Store at -80°C long term.
    Note
    For research use only .
灵璧县| 富锦市| 永寿县| 田东县| 泽州县| 郸城县| 正安县| 双桥区| 双流县| 亳州市| 淳安县| 青海省| 永安市| 永登县| 泊头市| 共和县| 长治市| 永清县| 长海县| 益阳市| 宁海县| 历史| 陈巴尔虎旗| 石台县| 安平县| 横山县| 霍州市| 盘山县| 读书| 兰州市| 滕州市| 盐池县| 大港区| 蒲江县| 柯坪县| 宁晋县| 金湖县| 会理县| 江达县| 陇川县| 肃宁县|